Efficacy and safety of calcineurin inhibitors use in patients with systemic lupus erythematosus
Systemic lupus erythematosus is a complex autoimmune disease in which more than one-third of patients develop lupus nephritis (LN), leading to chronic kidney disease and end-stage renal failure. The treatment of LN has always been a challenge. Tacrolimus is an effective immunosuppressant that has been increasingly used in recent years for the treatment of LN.
Authors
- А. М. Лила (ORCID: https://orcid.org/0000-0002-6068-3080)
- A. V. Datsina (ORCID: https://orcid.org/0000-0003-3051-219X)
- N. Yu. Nikishina (ORCID: https://orcid.org/0000-0002-4160-7218)
- Е. А. Асеева (ORCID: https://orcid.org/0000-0002-1663-7810)
- S. К. Solovyev (ORCID: https://orcid.org/0000-0002-5206-1732)
- E. T. Pletnev
Institutions
- Ministry of Health of the Russian Federation (RU)
- Association of Rheumatologists of Russia (RU)
Publication Details
- Journal
- Modern Rheumatology Journal
- Published
- 2025-06-24
- DOI
- https://doi.org/10.14412/1996-7012-2025-3-115-120
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00